{"paper_id":"3ecd28a0-affb-454c-ae2c-c6f7b2a8aa56","body_text":"Abstract\nKeywords: Endometriosis, treatment, aromatase inhibitors, angiogenesis\nMini-Reviews in Medicinal Chemistry\nTitle: Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant\nVolume: 9 Issue: 3\nAuthor(s): Warren B. Nothnick and Xuan Zhang\nAffiliation:\nKeywords: Endometriosis, treatment, aromatase inhibitors, angiogenesis\nAbstract: Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility. Current treatment regimes used to manage the disease do so by inducing a hypoestrogenic state. While the absence of circulating estrogen levels lead to a regression of the disease, this hypoestrogenism also induces many unpleasant side-effects. As such, these and other shortcomings of current drug therapies emphasize their limitations and the necessity for the development of novel endometriosis treatments. In this review, current therapies which target the biochemistry of the implant are discussed with emphasis on aromatase inhibitors, antiangiogenic compounds and vascular-disrupting agents.\nExport Options\nAbout this article\nCite this article as:\nNothnick B. Warren and Zhang Xuan, Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant, Mini-Reviews in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1389557510909030324\n| DOI https://dx.doi.org/10.2174/1389557510909030324 |\nPrint ISSN 1389-5575 |\n| Publisher Name Bentham Science Publishers |\nOnline ISSN 1875-5607 |\nCall for Papers in Thematic Issues\nAdvances and Novel Methodologies for the Development of Small-Molecule Drugs\nOver the past decade, small-molecule drugs have remained the dominant force among approved therapeutics. Recent advances in artificial intelligence and structural biology now enable researchers to discover novel targets for small molecule inhibitors with greater precision and to pursue rational drug design, markedly accelerating the development of new small molecule ...read more\nArtificial Intelligence and Generative Models in Medicinal Chemistry: From Molecular Design to Clinical Translation\nThis Thematic Issue will focus on the integration of artificial intelligence (AI) and generative models into medicinal chemistry, highlighting how these tools are reshaping drug discovery and development. The issue will provide readers with an overview of state-of-the-art algorithms, successful case studies, and translational opportunities, while also addressing current challenges ...read more\nBiodiversity, Ethnopharmacology, Biotechnology, Bioclimatology and Scientific Education Applied to Toxicology and One Health\nNeglected Tropical Diseases (NTDs) are represented by a group of distinct illnesses that affect the most vulnerable segment of the population, negatively impacting the Economy and Public Health. For example, like snakebite, leishmaniasis disproportionately affects vulnerable populations in tropical and subtropical regions. The search for safe drugs against various diseases ...read more\nCutting-Edge Medicinal Chemistry for Tropical Neglected Diseases: Recent Breakthroughs, Emerging Targets and Translational Strategies\nNeglected Tropical Diseases (NTDs) such as leishmaniasis, Chagas disease, schistosomiasis, filariasis, and dengue fever continue to impose a heavy health and economic burden on populations in developing regions. Despite affecting over a billion people globally, these diseases remain underfunded and understudied due to their limited commercial appeal. Recent advances in ...read more\n- Author Guidelines\n- Bentham Author Support Services (BASS)\n- Graphical Abstracts\n- Fabricating and Stating False Information\n- Research Misconduct\n- Post Publication Discussions and Corrections\n- Publishing Ethics and Rectitude\n- Increase Visibility of Your Article\n- Archiving Policies\n- Peer Review Workflow\n- Order Your Article Before Print\n- Promote Your Article\n- Manuscript Transfer Facility\n- Editorial Policies\n- Allegations from Whistleblowers\n- Announcements\nRelated Articles\nCurrent Drug Targets Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells\nCurrent Medicinal Chemistry Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review\nCurrent Genomics Morphofunctional Aspects of the Blood-Brain Barrier\nCurrent Drug Metabolism Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest Editor: Stefano Fiorucci)]\nCurrent Topics in Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders\nCurrent Pharmacogenomics and Personalized Medicine Mn-SOD and Chronic Inflammation of Gastric Mucosa\nAnti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Crocetin and Crocin from Saffron in Cancer Chemotherapy and Chemoprevention\nAnti-Cancer Agents in Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs\nCurrent Metabolomics Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents\nCurrent Pharmaceutical Design Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas\nCurrent Cancer Drug Targets Gap Junction Synthesis and Degradation as Therapeutic Targets\nCurrent Drug Targets Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties\nAnti-Cancer Agents in Medicinal Chemistry Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials\nCurrent Medicinal Chemistry The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy\nCurrent Pharmaceutical Design Novel Phytochemical Constituents and Anticancer Activities of the Genus, Typhonium\nCurrent Drug Metabolism Synthesis and Antitumor Activity Evaluation of 2-Aminothiazoles Appended 5-methylisoxazoline and Pyridine-piperazine Hybrid Molecules\nLetters in Organic Chemistry Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer\nCurrent Pharmaceutical Biotechnology Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs\nCurrent Pharmaceutical Design Alternative Viewpoint Against Breast Cancer Based on Selective Serotonin Receptors 5HTR3A and 5HTR2A Antagonists that can Mediate Apoptosis in MCF-7 Cell Line\nCurrent Drug Discovery Technologies","source_license":"public-domain-us","license_restricted":false}